Urovant Sciences Ltd

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference

Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference

Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

Urovant's valuation is reasonable when compared to the potential sales peak of Vibegron.

Urovant Sciences: A New Competitor In The Market For Overactive Bladder

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the H.C.

Urovant Sciences to Present at the H.C. Wainwright & Co.

Urovant Sciences Ltd. (UROV) CEO James Robinson on Q1 2020 Results - Earnings Call Transcript

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Fiscal First Quarter 2020 Results

Urovant Sciences Reports Fiscal First Quarter 2020 Results

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript

Urovant Sciences Ltd (UROV) on Q4 2019 Results - Earnings Call Transcript

Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching

Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year

The company has a diversified pipeline in that Vibegron is being explored for several indications that could bring in billions of dollars.

Urovant Is Severely Undervalued And Has A Major Catalyst Expected In 2020

Urovant Sciences' (UROV) CEO Keith Katkin on Q3 2019 Results - Earnings Call Transcript

Urovant Sciences Is A Hidden Gem With A Blockbuster Drug Likely To Be Approved This Year And 'Short Squeeze' Potential. PT: $43

Urovant Sciences Ltd (NASDAQ: UROV) has submitted a New Drug Application (NDA) to the U.S.

Urovant Sciences Trades Higher After Submitting Application For Overactive Bladder Treatment

Urovant Sciences Ltd. (UROV) CEO Keith Katkin on Q2 2019 Results - Earnings Call Transcript

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript

Finisar

Finisar falls, Urovant Sciences rises on financial results.

2 Stocks Move Strongly on Friday

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results - Earnings Call Transcript

News for Urovant Sciences Ltd Stock (UROV)